FDA Drug Safety Communication

September 26, 2017 1:57 PM | Anonymous

FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. This provides updated information to the FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning issued on August 31, 2016.

To learn more click here: https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm

Sign In

Log in


Latest News                     More News


Education





The mission of the American Osteopathic Academy of Addiction Medicine is to improve the health of individuals and families burdened with the disease of addiction.

Powered by Wild Apricot Membership Software